TY - JOUR
T1 - Near-infrared fluorescence imaging with an MET-targeting probe for biopsy site selection in patients with oral potentially malignant disorders
AU - Wang, Jingbo
AU - Shen, Xuemin
AU - Ma, Qifan
AU - Yang, Lin
AU - Zhou, Xiaoyu
AU - Wang, Luting
AU - Cui, Junqi
AU - Zhang, Chunye
AU - Li, Guojun
AU - Gross, Neil
AU - Li, Siyi
AU - Huang, Ruimin
AU - Zhan, Changyou
AU - Cheng, Zhen
AU - Wang, Kun
AU - Tian, Jie
AU - Yuan, Ying
AU - Tao, Xiaofeng
N1 - Publisher Copyright:
© 2025 The Authors
PY - 2025/3/18
Y1 - 2025/3/18
N2 - Accurate detection of malignant transformation in oral potentially malignant disorders (OPMDs) is crucial for guiding effective treatment and improving patient management. This study evaluates the potential of MET-binding peptide-indocyanine green (cMBP-ICG), a mesenchymal-epithelial transition factor (MET)-targeted near-infrared fluorescence imaging (NIRFI) probe, for biopsy site selection in OPMDs. Preclinical results demonstrate the superior accuracy of NIRFI-assisted biopsy over conventional oral examination (COE)-based biopsy in detecting high-grade dysplasia (HGD) or squamous cell carcinoma (SCC) and reducing missed detection rates. In a clinical trial with 50 patients, NIRFI-assisted biopsy achieves significantly higher diagnostic accuracy compared to COE-based biopsy (91% vs. 72%, p = 0.0005). These findings underscore the importance of NIRFI in enhancing diagnostic precision, supporting early detection and enabling timely and accurate treatment interventions for patients with OPMDs. The clinical trial is registered under the registration number ChiCTR2300074454.
AB - Accurate detection of malignant transformation in oral potentially malignant disorders (OPMDs) is crucial for guiding effective treatment and improving patient management. This study evaluates the potential of MET-binding peptide-indocyanine green (cMBP-ICG), a mesenchymal-epithelial transition factor (MET)-targeted near-infrared fluorescence imaging (NIRFI) probe, for biopsy site selection in OPMDs. Preclinical results demonstrate the superior accuracy of NIRFI-assisted biopsy over conventional oral examination (COE)-based biopsy in detecting high-grade dysplasia (HGD) or squamous cell carcinoma (SCC) and reducing missed detection rates. In a clinical trial with 50 patients, NIRFI-assisted biopsy achieves significantly higher diagnostic accuracy compared to COE-based biopsy (91% vs. 72%, p = 0.0005). These findings underscore the importance of NIRFI in enhancing diagnostic precision, supporting early detection and enabling timely and accurate treatment interventions for patients with OPMDs. The clinical trial is registered under the registration number ChiCTR2300074454.
KW - 4-NQO-induced OSCC model
KW - biopsy site selection
KW - fluorescence-guided biopsy
KW - mesenchymal-epithelial transition factor
KW - molecular imaging
KW - near-infrared targeted fluorescent imaging
KW - oral potentially malignant disorders
KW - oral squamous cell carcinoma
KW - topical application
UR - https://www.scopus.com/pages/publications/86000794946
U2 - 10.1016/j.xcrm.2025.101978
DO - 10.1016/j.xcrm.2025.101978
M3 - 文章
C2 - 39999837
AN - SCOPUS:86000794946
SN - 2666-3791
VL - 6
JO - Cell Reports Medicine
JF - Cell Reports Medicine
IS - 3
M1 - 101978
ER -